Aktienanalyse zu Valneva SE (VALN)VALNValneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It operates in the Healthcare sector.

Valneva SE is not a good buy right now due to its significant financial challenges and negative market sentiment. The stock is currently priced at $5.61, which is below the analyst price target of $4.90, indicating a potential downside. Additionally, the company reported a widening net loss of €63.3 million in H1 2026, compared to €20.8 million in the prior year, reflecting ongoing financial pressure. The recent revocation of the IXCHIQ vaccine license in the UK has also contributed to a 33% decline in stock value year-to-date, raising concerns about future revenue streams.